NCT03224507 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

March 14, 2018

Primary Completion Date

May 1, 2023

Study Completion Date

June 30, 2023

Conditions

Multiple Myeloma

Interventions

DRUG

KRdD followed by auto-HCT

Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.

DRUG

KRdD only

Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.

Trial Locations (4)

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt Ingram Cancer Center, Nashville

53792

University of Wisconsin, school of medicine and public health, Madison

97239

Oregon Health and Science University, Portland